# US 2003/0073634 A1 · Methods of treating obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073634 A1
- Document ID: US20030073634A1
- Status: Published application
- Kind: A1
- Application number: 10/226,579
- Filed: 2002-08-23
- Published: 2003-04-17
- Earliest claimed: 2001-08-24
- Inventors: Martin Myers
- Web page: https://patentgrep.com/patent/US20030073634A1

## CPC

- A61K 38/33: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K 38/1709: {from mammals}
- A61K 38/45: Transferases (2)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- G01N 33/502: {for testing non-proliferative effects}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods of modulating appetite, body weight and/or reproductive function in a mammal by modulating leptin receptor long form (LRb)-STAT3 signaling.

## Claims

### Claim 1

A method of modulating appetite or body weight in a mammal, comprising:
identifying a mammal in need of modulating appetite and/or body weight; and
administering to the mammal an agent that modulates leptin receptor long form (LRb)-STAT3 signaling.

### Claim 2 (depends on 1)

The method of claim 1, wherein appetite or body weight are modulated in the mammal without an effect on a reproductive function.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent promotes or increases LRb-STAT3 signaling, to thereby decrease appetite and/or body weight.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mammal is obese.

### Claim 5 (depends on 3)

The method of claim 3, wherein LRb-STAT3 signaling is increased by administering an agent that promotes an LRb-STAT3 signaling activity.

### Claim 6 (depends on 5)

The method of claim 5, wherein the agent that promotes LRb-STAT3 signaling activity increases or mimics the phosphorylation of the tyrosine located at about amino acid 1141 of human LRb or the corresponding tyrosine residue in another mammal.

### Claim 7 (depends on 5)

The method of claim 5, wherein the agent is a kinase or a kinase agonist.

### Claim 8 (depends on 5)

The method of claim 5, wherein the agent is a STAT3 or functional fragment thereof.

### Claim 9 (depends on 5)

The method of claim 5, wherein the agent is a small molecule that increases expression of STAT3, POMC or αMSH.

### Claim 10 (depends on 5)

The method of claim 5, wherein the agent is a nucleotide sequence encoding STAT3, POMC or αMSH.

### Claim 11 (depends on 1)

The method of claim 1, wherein LRb-STAT3 signaling is decreased, to thereby increase appetite or body weight.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mammal suffers from a disorder that causes weight loss or decreased appetite.

### Claim 13 (depends on 11)

The method of claim 11, wherein the mammal is, has or will be administered a treatment which results in weight loss or decreased appetite.

### Claim 14 (depends on 11)

The method of claim 11, wherein LRb-STAT3 signaling is decreased by administering an agent that decreases an LRb-STAT3 signaling activity.

### Claim 15 (depends on 14)

The method of claim 14, wherein the agent inhibits phosphorylation of human LRb Tyr1141 or a corresponding tyrosine in another mammal.

### Claim 16 (depends on 15)

The method of claim 15, wherein the agent is a kinase inhibitor or a phosphatase.

### Claim 17 (depends on 14)

The method of claim 14, wherein the agent is an anti-STAT3, anti-POMC or anti-αMSH antibody.

### Claim 18 (depends on 14)

The method of claim 14, wherein the agent is a STAT3, POMC or αMSH antisense molecule.

### Claim 19

A non-human transgenic rodent whose genome is heterozygous or homozygous for an engineered mutation in an LRb gene, wherein the mutation affects body weight or appetite in the mammal, but does not substantially affect reproductive function.

### Claim 20 (depends on 19)

The transgenic rodent of claim 19, wherein the mutation causes the disruption of LRb Tyr1138 in a mouse or a corresponding tyrosine in another mammal.

### Claim 21 (depends on 19)

The transgenic rodent of claim 19, wherein the rodent is a mouse.

### Claim 22

A cell having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-STAT3 signaling within the cell but does not cause a disruption in LRb-ERK signaling.

### Claim 23 (depends on 22)

The cell of claim 22, wherein LRb Tyr985 or a corresponding tyrosine is not mutated.

### Claim 24

A method of evaluating an agent for the ability to modulate appetite or body weight, the method comprising:
administering a test agent to a transgenic mammal having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-STAT3 signaling but not in LRb-ERK signaling; and
determining whether the test agent affects appetite or body weight in the transgenic mammal.

### Claim 25 (depends on 24)

The method of claim 24, wherein the transgenic mammal is evaluated for one or more of: (1) body weight; (2) glucose levels; (3) glucocorticoid levels; (4) leptin levels; (5) whole body triglyceride levels; (6) adiposity; (7) feeding behavior; (8) energy expenditure; (9) rate of weight gain; (10) insulin levels; (11) melanocortin levels; (12) ability to lactate post-partum; (13) fertility; (14) presence of estrous cycles; (15) morphology of reproductive tract; (16) animal length or height.

### Claim 26

A method of evaluating an agent for the ability to modulate appetite or body weight, the method comprising:
administering a test agent to a cell or tissue having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-STAT3 signaling but not in LRb-ERK signaling; and
determining whether the test agent affects LRb-STAT3 signaling in the cell or tissue.

### Claim 27 (depends on 26)

The method of claim 26, wherein determining whether the test agent affects LRb-STAT3 signaling comprises evaluating one or more of the following parameters: 1) phosphorylation state of LRb1138 (or a corresponding tyrosine); 2) Jak3 expression levels or activity; 3) STAT3 expression levels or activity; 4) POMC expression levels or activity; 5) αMSH expression levels or activity; 6) phosphorylation state of LRb985 (or a corresponding tyrosine); 7) ERK expression levels or activity; 8) SHP-2 expression levels or activity; and 9) SOCS3 expression levels or activity.

### Claim 28 (depends on 27)

The method of claim 27, further comprising the step of administering the test agent to an experimental animal.

### Claim 29 (depends on 24, 26)

The method of claim 24 or 26, wherein the test agent is selected from the group consisting of: a nucleic acid, a polypeptide and a small molecule.

### Claim 30

A method of determining if a subject is at risk for obesity, the method comprising: (a) evaluating a LRb-STAT3 activity in the subject, and (b) correlating the LRb-STAT3 activity to a risk for obesity, wherein a lower LRb-STAT3 activity in the subject compared to a reference value indicates that the subject is at risk for obesity.

### Claim 31

A method of determining if a subject is at risk for obesity, the method comprising: (a) determining the presence or absence of a genetic lesion in the LRb gene of a subject, wherein the genetic lesion disrupts the tyrosine located at about amino acid 1141 of LRb, and (b) correlating the presence or absence of the genetic lesion to a risk for obesity, wherein the presence of the genetic lesion is indicative of risk for obesity in the subject.

### Claim 32

A method of modulating fertility in a mammal, the method comprising modulating LRb-ERK signaling to thereby modulate fertility.

### Claim 33

A method of modulating height in a mammal, the method comprising modulating LRb-ERK signaling to thereby modulate height.

### Claim 34

A non-human transgenic rodent whose genome is heterozygous or homozygous for an engineered mutation in an LRb gene, wherein the mutation affects reproductive function or height in the mammal, but does not substantially affect body weight or appetite.

### Claim 35

A cell having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-ERK signaling within the cell but does not cause a disruption in LRb-STAT3 signaling.

### Claim 36 (depends on 35)

The cell of claim 35, wherein LRb Tyr1141 or a corresponding tyrosine is not mutated.

### Claim 37

A method of evaluating an agent for the ability to modulate reproductive function or height, the method comprising:
administering a test agent to a transgenic mammal having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-ERK signaling but not in LRb-STAT signaling; and
determining whether the test agent affects reproductive function or height in the transgenic mammal.

### Claim 38

A method of evaluating an agent for the ability to modulate reproductive function or height, the method comprising:
administering a test agent to a cell or tissue having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-ERK signaling but not in LRb-STAT3 signaling; and
determining whether the test agent affects LRb-ERK signaling in the cell or tissue.

### Claim 39 (depends on 38)

The method of claim 38, further comprising the step of administering the test agent to an experimental animal.

### Claim 40

A method of determining if a subject is at risk for a reproductive disorder, the method comprising:
(a) evaluating a LRb-ERK activity in the subject, and (b) correlating the LRb-ERK activity to a risk for reproductive disorder, wherein a lower LRb-ERK activity in the subject compared to a reference value indicates that the subject is at risk for reproductive disorder.

### Claim 41

A method of determining if a subject is at risk for reproductive disorder, the method comprising:
(a) determining the presence or absence of a genetic lesion in the LRb gene of a subject, wherein the genetic lesion disrupts the tyrosine located at about amino acid 985 of LRb, and
(b) correlating the presence or absence of the genetic lesion to a risk for reproductive disorder, wherein the presence of the genetic lesion is indicative of risk for reproductive disorder in the subject.

### Claim 42

An isolated LRb polypeptide wherein the tyrosine residue corresponding to murine LRb Tyr 1138 has been altered, but the amino acid residue corresponding to murine LRb Tyr 985 has not been altered.

### Claim 43 (depends on 42)

The polypeptide of claim 42, wherein the polypeptide comprises SEQ ID NO:4 wherein the amino acid residue at position 1141 has been altered.

### Claim 44 (depends on 42)

The polypeptide of claim 42, wherein the polypeptide comprises SEQ ID NO:2 wherein the amino acid residue at position 1138 has been altered.
